Literature DB >> 36105047

Down-regulation of NOTCH1 and PKM2 can inhibit the growth and metastasis of colorectal cancer cells.

Jia Wang1, Meijuan Sun2, Rong Ma3, Gaobo Wang1, Wenqing Li1, Bowei Yang1, Yang Yang1.   

Abstract

BACKGROUND: Previous studies have revealed the overexpression of Notch receptor 1 (NOTCH1) and pyruvate kinase M2 (PKM2) in colorectal cancer (CRC) tissue and their relationship to disease development. However, whether there is synergy between PKM2 and NOTCH1 needs to be verified. This study aims to analyze the mechanism and relationship between NOTCH1 and PKM2 in CRC.
METHODS: Immunohistochemistry was used to measure the expression of NOTCH1 and PKM2 in colorectal cancer, and the correlation between them was analyzed by Pearson test. The protein and mRNA expressions in CRC cell lines were determined by western blot (WB) and real-time quantitative reverse transcription PCR (qRT-PCR). Compound 3K and tangeretin (TGN) were used to inhibit the expressions of PKM2 and NOTCH1, respectively. The wound healing assay and CCK-8 assay were applied to measure the migration and proliferation of cancer cells.
RESULTS: Immunohistochemical analysis showed that NOTCH1 and PKM2 were overexpressed in patients with colorectal cancer, and patients with overexpression showed a higher number of lymph node metastases and high tumor stage (III+IV) (P<0.05). In addition, Pearson test showed that the level of NOTCH1 was positively correlated with the level of PKM2 (P<0.05). WB and qRT-PCR showed that the protein and mRNA levels of NOTCH1 and PKM2 in colorectal cancer cells were significantly up-regulated (P<0.05). The inhibition of PKM2 and NOTCH1 had a synergistic effect on reducing the invasion and proliferation of CRC cells.
CONCLUSION: NOTCH1 and PKM2 are highly expressed in CRC patients. Inhibiting the expression of NOTCH1 and PKM2 can inhibit the growth and metastasis of CRC cells, providing therapeutic targets for the treatment of CRC. AJTR
Copyright © 2022.

Entities:  

Keywords:  NOTCH1; colorectal cancer; compound 3k; pyruvate kinase M2; synergistic impact; tangeretin

Year:  2022        PMID: 36105047      PMCID: PMC9452328     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  19 in total

1.  Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.

Authors:  J Chen; J Xie; Z Jiang; B Wang; Y Wang; X Hu
Journal:  Oncogene       Date:  2011-04-25       Impact factor: 9.867

2.  Control of neuronal cell fate and number by integration of distinct daughter cell proliferation modes with temporal progression.

Authors:  Carina Ulvklo; Ryan MacDonald; Caroline Bivik; Magnus Baumgardt; Daniel Karlsson; Stefan Thor
Journal:  Development       Date:  2012-01-12       Impact factor: 6.868

3.  A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

Authors:  John J Arcaroli; W M Tai; Ryan McWilliams; Stacey Bagby; Patrick J Blatchford; Marileila Varella-Garcia; Alicia Purkey; Kevin S Quackenbush; Eun-Kee Song; Todd M Pitts; Dexiang Gao; Chris Lieu; Martine McManus; Aik Choon Tan; Xianxian Zheng; Qin Zhang; Mark Ozeck; Peter Olson; Zhi-Qin Jiang; Scott Kopetz; Antonio Jimeno; Stephen Keysar; Gail Eckhardt; Wells A Messersmith
Journal:  Int J Cancer       Date:  2015-07-22       Impact factor: 7.396

4.  Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet.

Authors:  H J Hacker; P Steinberg; P Bannasch
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

5.  High level of Notch1 protein is associated with poor overall survival in colorectal cancer.

Authors:  Dake Chu; Yunming Li; Weizhong Wang; Qingchuan Zhao; Jipeng Li; Yuanyuan Lu; Mengbin Li; Guanglong Dong; Hongwei Zhang; Huahong Xie; Gang Ji
Journal:  Ann Surg Oncol       Date:  2010-01-08       Impact factor: 5.344

Review 6.  Worldwide burden of colorectal cancer: a review.

Authors:  Pasqualino Favoriti; Gabriele Carbone; Marco Greco; Felice Pirozzi; Raffaele Emmanuele Maria Pirozzi; Francesco Corcione
Journal:  Updates Surg       Date:  2016-04-11

Review 7.  Pyruvate kinase M2 and cancer: an updated assessment.

Authors:  Mohd Askandar Iqbal; Vibhor Gupta; Prakasam Gopinath; Sybille Mazurek; Rameshwar N K Bamezai
Journal:  FEBS Lett       Date:  2014-04-18       Impact factor: 4.124

8.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

9.  Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism.

Authors:  Takeharu Shiroki; Misa Yokoyama; Nobuhiro Tanuma; Ryuhei Maejima; Keiichi Tamai; Kazunori Yamaguchi; Tomoyuki Oikawa; Tetsuya Noguchi; Koh Miura; Tsuneaki Fujiya; Hiroshi Shima; Ikuro Sato; Naoko Murata-Kamiya; Masanori Hatakeyama; Katsunori Iijima; Tooru Shimosegawa; Kennichi Satoh
Journal:  Cancer Sci       Date:  2017-04-24       Impact factor: 6.716

Review 10.  A Review on Notch Signaling and Colorectal Cancer.

Authors:  Ashish Tyagi; Arun K Sharma; Chendil Damodaran
Journal:  Cells       Date:  2020-06-25       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.